Tech Company Financing Transactions

Harpoon Therapeutics Funding Round

OrbiMed, Arix Bioscience and Cormorant Asset Management participated in a $70 million Series C funding round for Harpoon Therapeutics. The financing round was announced on 11/13/2018.

Transaction Overview

Company Name
Harpoon Therapeutics
Announced On
11/13/2018
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series C
Investors

OrbiMed (Lead Investor)

Arix Bioscience (Mark Chin)

Cormorant Asset Management

Lilly Asia Ventures

MPM Capital (Luke Evnin)

New Leaf Venture Partners (Ron Hunt)

NS Investment

Oncology Impact Fund

Ridgeback Capital

Taiho Ventures (Sakae Asanuma)

Proceeds Purpose
Harpoon intends to use the proceeds from the financing to support further advancement of its immunotherapy programs based on its TriTAC (Tri-specific T cell Activating Construct) and ProTriTAC (Protease-activated Tri-specific T Cell Activating Construct) platforms, which are designed to harness the natural power of the body's immune system to fight cancer and other diseases.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
131 Oyster Point Blvd. 300
San Francisco, CA 94080
USA
Phone
(650) 443-7400
Website
www.harpoontx.com
Email Address
[email protected]
Overview
Harpoon Therapeutics (Nasdaq: HARP) is an immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.
Profile
Harpoon Therapeutics LinkedIn Company Profile
Social Media
Harpoon Therapeutics Company Twitter Account
Company News
Harpoon Therapeutics News
Facebook
Harpoon Therapeutics on Facebook
YouTube
Harpoon Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Gerald McMahon
  Gerald McMahon LinkedIn Profile  Gerald McMahon Twitter Account  Gerald McMahon News  Gerald McMahon on Facebook
Chief Financial Officer
Georgia Erbez
  Georgia Erbez LinkedIn Profile  Georgia Erbez Twitter Account  Georgia Erbez News  Georgia Erbez on Facebook
Chief Medical Officer
Natalie Sacks
  Natalie Sacks LinkedIn Profile  Natalie Sacks Twitter Account  Natalie Sacks News  Natalie Sacks on Facebook
Chief Scientific Officer
Holger Wesche
  Holger Wesche LinkedIn Profile  Holger Wesche Twitter Account  Holger Wesche News  Holger Wesche on Facebook
Vice President
Che-Leung Law
  Che-Leung Law LinkedIn Profile  Che-Leung Law Twitter Account  Che-Leung Law News  Che-Leung Law on Facebook
VP - Bus. Development
Rachael Lester
  Rachael Lester LinkedIn Profile  Rachael Lester Twitter Account  Rachael Lester News  Rachael Lester on Facebook
VP - Finance
Christopher Whitmore
  Christopher Whitmore LinkedIn Profile  Christopher Whitmore Twitter Account  Christopher Whitmore News  Christopher Whitmore on Facebook
VP - Product Management
Susan Jones
  Susan Jones LinkedIn Profile  Susan Jones Twitter Account  Susan Jones News  Susan Jones on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/12/2018: Idelic venture capital transaction
Next: 11/13/2018: AEGEA venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.